Status: Not yet recruiting
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls/women in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.
Participants needed: 1,266
Trial details
Phase: Phase 4Age: 9-20Biological sex: AllType: InterventionalSponsor: International Agency for Research on CancerUpdated: Mar 24, 2026Locations: 1
Eligibility criteria
Girl/woman between 9 and 20 years of age and boy between the age of 9 and 14 yea... [+4]
Participants who are sexually active and missed their last menstrual period will... [+15]